Abstract:Background and objectives: Recent advances in Automated Insulin Delivery systems have been shown to dramatically improve glycaemic control and reduce the risk of hypoglycemia in people with type 1 diabetes. However, they are complex systems that require specific training and are not affordable for most. Attempts to reduce the gap with closed-loop therapies using advanced dosing advisors have so far failed, mainly because they require too much human intervention. With the advent of smart insulin pens, one of the main constraints (having reliable bolus and meal information) disappears and new strategies can be employed. This is our starting hypothesis, which we have validated in a very demanding simulator. In this paper, we propose an intermittent closed-loop control system specifically intended for multiple daily injection therapy to bring the benefits of artificial pancreas to the application of multiple daily injections. Methods: The proposed control algorithm is based on model predictive control and integrates two patient-driven control actions. Correction insulin boluses are automatically computed and recommended to the patient to minimize the duration of hyperglycemia. Rescue carbohydrates are also triggered to avoid hypoglycemia episodes. The algorithm can adapt to different patient lifestyles with customizable triggering conditions, closing the gap between practicality and performance. The proposed algorithm is compared with conventional open-loop therapy, and its superiority is demonstrated through extensive in silico evaluations using realistic cohorts and scenarios. The evaluations were conducted in a cohort of 47 virtual patients. We also provide detailed explanations of the implementation, imposed constraints, triggering conditions, cost functions, and penalties for the algorithm. Results: The in-silico outcomes combining the proposed closed-loop strategy with slow-acting insulin analog injections at 09:00 h resulted in percentages of time in range (TIR) (70-180 mg/dL) of 69.5%, 70.6%, and 70.4% for glargine-100, glargine-300, and degludec-100, respectively, and injections at 20:00 h resulted in percentages of TIR of 70.5%, 70.3%, and 71.6%, respectively. In all the cases, the percentages of TIR were considerably higher than those obtained from the open-loop strategy, being only 50.7%, 53.9%, and 52.2% for daytime injection and 55.5%, 54.1%, and 56.9% for nighttime injection. Overall, the occurrence of hypoglycemia and hyperglycemia was notably reduced using our approach. Conclusions: Event-triggering model predictive control in the proposed algorithm is feasible and may meet clinical targets for people with type 1 diabetes.

Intraperitoneal Insulin Delivery: Evidence of a Physiological Route for Artificial Pancreas From Compartmental Modeling

Artificial connection between glucose sensing and insulin delivery: implications of peritoneal administration

Enhancing Therapeutic Insulin Transport from Macroencapsulated Islets Using Sub-Minute Pressure at Physiological Levels

Embedded Model Predictive Control for a Wearable Artificial Pancreas

Pulsatile Zone MPC with asymmetric stationary cost for artificial pancreas based on a non-standard IOB constraint

Feasibility of Closed-Loop Insulin Delivery with a Pregnancy-Specific Zone Model Predictive Control Algorithm

Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes

Run-to-Run Tuning of Model Predictive Control for Type 1 Diabetes Subjects: In Silico Trial

Model Predictive Control (MPC) of an Artificial Pancreas with Data-Driven Learning of Multi-Step-Ahead Blood Glucose Predictors

Model Based Study on Monitoring Ketone Bodies to Improve Safety in Intensive Insulin Therapy

Application of Zone Model Predictive Control Artificial Pancreas During Extended Use of Infusion Set and Sensor: A Randomized Crossover-Controlled Home-Use Trial

A novel pulse-modulated closed-loop artificial pancreas based on intravenous administration of insulin and glucagon

The artificial pancreas: two alternative approaches to achieve a fully closed-loop system with optimal glucose control

Design and Validation of an Open-Source Closed-Loop Testbed for Artificial Pancreas Systems

Intermittent closed-loop blood glucose control for people with type 1 diabetes on multiple daily injections

Strategies for Extended Lifetime of Implantable Intraperitoneal Insulin Catheters.

Neural-Net Artificial Pancreas: A Randomized Crossover Trial of a First-in-Class Automated Insulin Delivery Algorithm

Adaptive Model Predictive Control with Particle Filter for Artificial Pancreas

An in-silico modeling approach to separate exogenous and endogenous plasma insulin appearance, with application to inhaled insulin

Algorithms for a Closed-Loop Artificial Pancreas: The Case for Model Predictive Control